TP53 and breast cancer: These results show that the adverse prognostic impact of p53 LOH in epithelial tumors (i.e., NSCLC and breast carcinoma) is greatly improved with simultaneous loss of the hDMP1, the result of which are consistent with favorable impact of hDMP1 LOH in NSCLC (this study) and breast cancer [42].